Noëlle Warmenhoven

‼️ New preprint ‼️
How do amyloid-β (Aβ) and tau drive Alzheimer’s disease over time?
We introduce a parsimonious, mechanism-based dynamical ATN (dATN) model to simulate longitudinal imaging biomarkers. A short thread 👇
Preprint: www.biorxiv.org/content/10.6...

Prediction of continuous amyloid positron emission tomography with fluid measures of phosphorylated tau and β-amyloid | EMBO Molecular Medicine imageimageMachine-learning models using CSF and plasma biomarkers accurately predicted quantitative Aβ-PET burden. Distinct contributions of soluble Aβ42/Aβ40 and plasma P-tau217 reveal their role in ...

New paper out in EMBO Mol Med! We use machine learning to predict Aβ-PET burden from fluid biomarkers. www.embopress.org/doi/full/10....

Key findings:
- Performance R² = 0.79
- CSF Aβ42/Aβ40 most predictive of Aβ plaque presence
- Plasma p-tau217 best for tracking increasing amyloid plaque burden

🚨Postdoc position open at @BarcelonaBeta🚨
We're looking someone to work on a project at the intersection of cardiovascular and neurodegenerative research 🫀🧠
Fully funded position!!!
More details: www.imim.cat/media/upload...
Please share!
#Alzheimer's #ENDALZ

Plasma P-Tau217 to Identify Preclinical AD This cohort study evaluates the use of plasma phosphorylated tau 217 in identifying preclinical Alzheimer disease in individuals with amyloid β pathology.

🚨Paper alert🚨
New publication in JAMA Neurology led by @gsalvado.bsky.social. In a multicentric study, we examined the clinical utility to assess preclinical #Alzheimer’s disease in cognitively unimpaired individuals.

jamanetwork.com/journals/jam...

A 🧵...

Primary care detection of Alzheimer’s disease using a self-administered digital cognitive test and blood biomarkers - Nature Medicine | The Swedish BioFINDER study New publication in Nature Medicine!   In this study, led by PhD students Pontus Tideman and Linda Karlsson, we demonstrate that a brief, self-administered cognitive test battery can reliably identify ...

🚨New publication in Nature Medicine!
In this study, we demonstrate that a brief, self-administered cognitive test battery can reliably identify individuals with cognitive impairment in a primary care setting.
More details: linkedin.com/feed/update/...
Full paper: www.nature.com/articles/s41...

New paper published today in @nataging.nature.com !
This one took some time but it's always a pleasure working hand in hand with Laia Montoliu-Gaya and the Gothenburg team. Thanks also to the McGill group for also collaborating with TRIAD data.
A 🧵 below.
#ENDALZ

Very grateful to have had the opportunity to share our work comparing the FDA-approved p-tau217/AB42 blood test to CSF!

‼️NEW PREPRINT‼️

What if you could take a normal 3T T1w MRI and make it look like it was acquired from a 7T scanner?

That's exactly what we do using AI in our new preprint!

Link: arxiv.org/abs/2507.13782

#neuroskyence #neurosky #compneuro #AI #datascience #neurology #mrisky #neuroimaging

Prediction of amyloid and tau brain deposition and cognitive decline in people with Down syndrome using plasma biomarkers: a longitudinal cohort study Baseline and longitudinal plasma p-tau217 were associated with subsequent decline in global cognition, progression to dementia, and increased tau burden, whereas baseline p-tau217 and GFAP were associ...

New manuscript alert! Are plasma biomarkers🩸 predictive of Alzheimer’s disease progression in Down Syndrome (DS)? Our new study in collaboration with the ABC-DS consortium has now been published in @thelancetneuro.bsky.social: www.thelancet.com/journals/lan...

✨ REMINDER!! ✨ please help me gather the most inspiring papers of the last year (including your own!!) by completing the survey below! 🙏

Looking so much forward to presenting the @NeuroimagingPIA year in review talk at #AIC2025 in Toronto this July!! 🤩

alz.surveymonkey.com/r/923BTQK

How does the brain reorganize in the context of age and AD?

Are functional changes in age and AD similar?

Are these changes dynamic across the age/AD spectrum?

We unpack these questions in a sample of N=973 with AD biomarkers

Preprint: tinyurl.com/ymv8s7h8

⬇️🧵

1/

🚨New paper in Alzheimer's & Dementia! We investigate whether p-tau immuno-assays selectively quantifying low-molecular-weight (LMW) tau (CNS) are more specific for tau changes in AD vs ALS than assays not differentiating between LMW and high-MW (PNS) tau👇https://pubmed.ncbi.nlm.nih.gov/40289884/

The preprint of my first PhD project is live! 🧠 Find the link to the manuscript and read about the key findings below. 👇 #alzheimersdisease #neuroimaging #tau #amyloid #mri #pet #biofinder

Simple, yet effective way to early detect Alzheimer's disease A simpler method of analysing blood samples for Alzheimer’s disease has been tested in a large multicentre study, led by Lund University in Sweden.

A new, simpler and cheaper analytical method for the early detection of #Alzheimers disease could help bring #blood tests into the #healthcare system globally, according to a new study co-authored by @noellewarmenhoven.bsky.social from 🇸🇪 @lund-university.bsky.social.

Plasma phospho-tau217 for Alzheimer’s disease diagnosis in primary and secondary care using a fully automated platform - Nature Medicine Among 1,767 patients in 5 centers, a fully automated blood test showed high accuracy for Alzheimer’s pathology in secondary and primary care using a predefined cutoff.

New manuscript alert! Can blood-based biomarkers measured on a fully automated platform accurately identify Alzheimer’s disease (AD) pathology?🩸 Our new multi-cohort study has now been published in
@naturemedicine.bsky.social: nature.com/articles/s41.... A thread🧵

Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer’s disease - Nature Medicine Plasma eMTBR-tau243 is a specific biomarker of tau tangles in Alzheimer’s disease and enables the detecting and tracking of Alzheimer’s clinical impairment.

‼️New publication on a novel plasma biomarker for tau pathology 🧠🧪 in @naturemedicine.bsky.social led by Kanta Horie & @gsalvado.bsky.social:
📖 www.nature.com/articles/s41...

In this study, we investigated plasma eMTBR-tau243, which closely reflects tau tangle pathology in Alzheimer’s disease (AD).

An Alzheimer’s Blood Test Might Predict Advanced Disease The test, which is not yet commercially available, focuses on a different form of the protein tau.

time.com/7273006/alzh...